PitchBook-医疗保健未来报告：减肥药（英）-2023.9-10页_238kb

Healthcare Future Report Summary: Weight Loss Drugs

Introduction

GLP-1 agonist drugs for diabetes and weight loss are transforming healthcare by addressing obesity and related conditions. This report outlines short- and long-term implications for biopharma, digital health, healthcare services, medtech, and healthcare IT.

Background

Key GLP-1 agonists include Ozempic, Wegovy, and Mounjaro, approved for diabetes and weight loss with trials showing significant weight reduction and cardiovascular benefits, such as up to 28% weight loss from retatrutide.

Payer Coverage

Payers face coverage challenges due to high costs; Medicare prohibits weight loss coverage but may expand it, while Medicaid and ACA plans show variable coverage. Prior authorization is common, and payer tech may adapt to manage demand.

Biopharma

Short-term: Big players like Novo Nordisk and Eli Lilly lead; funding and M&A are high. Long-term: Drug indications, efficacy, and delivery methods (e.g., oral drugs) will drive market growth, with gene therapies as future innovations.

Digital Health

Short-term: Telehealth services pivot to weight loss; established nutrition platforms face pressure. Long-term: Fitness and wellness apps benefit from population weight reduction; new startups offer telehealth and prescription management services.

Healthcare Services

Short-term: Demand for clinical trial sites in cardiovascular and metabolic research increases. Bariatric surgery volumes drop due to drug alternatives. Long-term: Elder care demand rises with longer life expectancies.

Medtech

Short-term: Limited impact, but injectable packaging demand rises. Long-term: Devices like CPAPs and diabetes monitors may see reduced demand due to weight loss effects.

Healthcare IT

Short-term: B2B telemedicine grows with prescriptions. Long-term: Prior authorization burdens increase, boosting workflow automation and payment integrity tech.